Trials / Completed
CompletedNCT02916446
Safety Study of Viaskin Peanut to Treat Peanut Allergy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 393 (actual)
- Sponsor
- DBV Technologies · Industry
- Sex
- All
- Age
- 4 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Viaskin Peanut 250 mcg | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-09-22
- Completion
- 2020-10-07
- First posted
- 2016-09-27
- Last updated
- 2021-02-03
Locations
32 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02916446. Inclusion in this directory is not an endorsement.